Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Macarena I de la Fuente

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Continuum (Minneapolis, Minn.)|December 12, 2023
Adult-type Diffuse GliomasMacarena I de la Fuente
Current Opinion in Neurology|November 11, 2022
Targeting IDH1/IDH2 mutations in gliomasMacarena I de la Fuente
Advances in Cancer Research|July 17, 2025
Molecularly driven therapies in the treatment of primary brain tumorsRuham Alshiehk Nasany, Macarena I de la Fuente
Annals of Clinical and Translational Neurology|October 31, 2014
The role of ventriculoperitoneal shunting in patients with supratentorial gliomaMacarena I de la Fuente, Lisa M DeAngelis
British Journal of Haematology|September 5, 2019
Central nervous system emergencies in haematological malignanciesMacarena I de la Fuente, Juan Pablo Alderuccio, Izidore S Lossos
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 11, 2025
Incorporating Targeted Therapy Into Neuro-Oncology PracticeMarjolein Geurts, Juan B Blaquier, Maarten Wijnenga, et al.
CNS Oncology|July 28, 2020
Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, <i>IDH1</i>-mutant glioblastoma: a case report from a Phase I studyDalissa Tejera, Marina Kushnirsky, Sakir H Gultekin, et al.
Journal of Neuro-Oncology|May 21, 2017
The role of bevacizumab in the treatment of glioblastomaRoberto Jose Diaz, Sheikh Ali, Mehreen Gull Qadir, et al.
Leukemia & Lymphoma|September 22, 2016
Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiencesMacarena I de la Fuente, Aya Haggiagi, Adrienne Moul, et al.
American Journal of Hematology|January 22, 2019
Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphomaMacarena I de la Fuente, Juan Pablo Alderuccio, Isildinha M Reis, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Continuum (Minneapolis, Minn.)|December 12, 2023
Adult-type Diffuse GliomasMacarena I de la Fuente
Current Opinion in Neurology|November 11, 2022
Targeting IDH1/IDH2 mutations in gliomasMacarena I de la Fuente
Advances in Cancer Research|July 17, 2025
Molecularly driven therapies in the treatment of primary brain tumorsRuham Alshiehk Nasany, Macarena I de la Fuente
Annals of Clinical and Translational Neurology|October 31, 2014
The role of ventriculoperitoneal shunting in patients with supratentorial gliomaMacarena I de la Fuente, Lisa M DeAngelis
British Journal of Haematology|September 5, 2019
Central nervous system emergencies in haematological malignanciesMacarena I de la Fuente, Juan Pablo Alderuccio, Izidore S Lossos
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 11, 2025
Incorporating Targeted Therapy Into Neuro-Oncology PracticeMarjolein Geurts, Juan B Blaquier, Maarten Wijnenga, et al.
CNS Oncology|July 28, 2020
Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, <i>IDH1</i>-mutant glioblastoma: a case report from a Phase I studyDalissa Tejera, Marina Kushnirsky, Sakir H Gultekin, et al.
Journal of Neuro-Oncology|May 21, 2017
The role of bevacizumab in the treatment of glioblastomaRoberto Jose Diaz, Sheikh Ali, Mehreen Gull Qadir, et al.
Leukemia & Lymphoma|September 22, 2016
Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiencesMacarena I de la Fuente, Aya Haggiagi, Adrienne Moul, et al.
American Journal of Hematology|January 22, 2019
Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphomaMacarena I de la Fuente, Juan Pablo Alderuccio, Isildinha M Reis, et al.
Pageof 4